Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

This review aims to outline the most up-to-date knowledge of pancreatic adenocarcinoma
risk, diagnostics, treatment and outcomes, while identifying gaps that aim to stimulate further …

Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy and
estimated to become the second leading cause of cancer-related deaths by 2030. Although …

Background Modern pancreatic cancer surgery changed with the introduction of effective
neoadjuvant therapies. Complete tumor resection is the mainstay for long-term, disease …

Background Neoadjuvant therapy is an important strategy for locally advanced pancreatic
cancer (PDAC) as resection rates increase with modern chemotherapy regimens even in …

Background Pancreaticoduodenectomy (PD) is one of the most technically difficult
abdominal operations. Recent advances have allowed surgeons to attempt PD using …

In this population-based retrospective study, we aimed to investigate the association
between age at diagnosis and prognosis of pancreatic cancer (PC) patients using data from …

Classification and guidelines of hemorrhoidal disease are based on the subdivision in
Grades of prolapse followed by any aspect related to both the treatment and its technique …

Although the overall five-year survival of patients with pancreatic ductal adenocarcinoma
(PDAC) is dismal, there are survival differences between cases with clinically and …